All In Biotech

Drug Trial Radar · NCT06532578

Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus

A Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Trial to Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Aug 13, 2024

Primary completion

Dec 15, 2025

Study completion Apr 1, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.

Conditions

  • Overweight and Obesity

Interventions

  • CPX101 or placebo 120mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 160mg Q4WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 160mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 240mg Q4WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 240mg Q2WBiological

    Subcutaneous injection of CPX101 or placebo

  • CPX101 or placebo 320mg Q2WBiological

    CPX101 or placebo 320mg Q2W

  • CPX101 or placebo 360mg Q4WBiological

    CPX101 or placebo 360mg Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of CPX101 in body weight loss in KgTime frame: Up to 24 weeks after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Paratus Clinical Research

    Chatswood, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.